Napo Pharma and Glenmark Pharma sign agreement returning rights in 141 countries to Napo
Jaguar Health announced that its subsidiary, Napo Pharmaceuticals, has entered into a Termination, Asset Transfer and Transition Agreement with India-based Glenmark Pharmaceuticals. Glenmark is Napo’s primary manufacturer of crofelemer, the API in Mytesi®. September 25, 2017